Recombinant Human PCK1/PEPCK1 His-tag Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 11818-PK

Catalog #
Availability
Size / Price
Qty
11818-PK-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

E. coli

Accession #

P35558.3

Conjugate

Unconjugated

Applications

Enzyme Activity

View all PCK1 Proteins and Enzymes »

Product Specifications

Source

E. coli-derived human PCK1 protein
Pro2-Met622, with an N-terminal Met and 6-His tag

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Met

Predicted Molecular Mass

70 kDa

SDS-PAGE

61-68 kDa, under reducing conditions.

Activity

Measured by its ability to transfer phosphate from adenosine triphosphate (ATP) to Oxaloacetic Acid.
The specific activity is >200 pmol/min/μg, as measured under the described conditions.

Scientific Data Images for Recombinant Human PCK1/PEPCK1 His-tag Protein, CF

Recombinant Human PCK1/PEPCK1 His-tag Enzyme Activity.

Recombinant Human PCK1/PEPCK1 His-tag Protein (Catalog # 11818-PK) is measured by its ability to transfer phosphate from adenosine triphosphate (ATP) to Oxaloacetic Acid.

Recombinant Human PCK1/PEPCK1 His-tag SDS-PAGE.

2 μg/lane of Recombinant Human PCK1/PEPCK1 His-tag (Catalog # 11818-PK) was resolved with SDS-PAGE under reducing (R) condition and visualized by Coomassie® Blue staining, showing bands at 61-68 kDa, under reducing conditions.

Formulation, Preparation and Storage

11818-PK
Formulation Supplied as a 0.2 μm filtered solution in Tris, NaCl and TCEP. 
Shipping The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, -20 to -70 °C under sterile conditions after opening.

Background: PCK1

Recombinant human cytosolic Phosphoenolpyruvate carboxykinase (PEPCK1), also known as Serine protein kinase PCK1, is the cytosolic form of two highly conserved rate-limiting mammalian PEPCK isoenzymes that catalyze the generation of phosphoenolpyruvate (PEP) from oxaloacetate (OAA) in gluconeogenesis. While both forms are structurally and functionally similar, they have differing activity and expression in tissues which leads to distinct biological function (1). While PEPCK2 is widely expressed and induced by stress, PEPCK1 is highly expressed in the liver, kidney, gastrointestinal tract and adipose tissue (1). PEPCK1 is a monomeric protein that has a conserved functional active site and contains carboxylate group-binding motifs for PEP and OAA guanine- and ribose-binding sites that form an unusual pocket nucleotide binding site for GTP nucleotides, and a Mn-binding site (2-4). PEPCK1 can be acetylated to regulate its activity (1, 5). Due to the critical nature of PEPCK1 as a rate-limiting enzyme in gluconeogenesis, misregulation of the enzyme is problematic. Mutations in the gene can lead to autosomal recessive metabolic disorders known as phosphoenolpyruvate carboxykinase deficiency that can be fatal (1, 6, 7), downregulation can lead to metabolic associated fatty liver disease (MAFLD) (8), and overactivation of PEPCK activity has been linked to diabetes (9). Given its role as a control point in metabolic gluconeogenesis and its responsiveness to glucocorticoids and insulin, PEPCK1 is of interest for a potential therapeutic target in diabetes and obesity (1, 10, 11). In addition, given its role in metabolic regulation directly or via kinase sterol regulatory element-binding protein (srebp) activation to regulate the transcription of lipogenesis genes, altered PEPCK1 function has been reported in many cancers including liver, non-small cell lung cancer (NSCLC), and esophageal melanoma (1, 12-14). Expression changes of PEPCK1 were also linked to prognosis in several cancers including lung, liver, pancreatic, esophageal and renal carcinoma (13-18). PEPCK1 is downregulated in many tumors of gluconeogenic organs (HCC and RCC) and has anti-tumor effects while PEPCK1 is upregulated and oncogenic in tumors originating from non-gluconeogenic organs (CRC, lung cancer, melanoma, breast cancer, pancreatic cancer, and gastric cancer) making PEPCK1 a target for broad therapeutic application in cancer treatments (4, 15-18).

References

  1. Shuo, Y. et al. (2021) Mol. Metab. 53:101257.
  2. Dunten, P. et al. (2002) J. Mol. Biol. 316:257.
  3. Delbaere, L.T. et. al. (2004) Biochim. Biophys. Acta. 1697:271.
  4. Xiang, J. et. al. (2022) Genes Dis. 10:101.  
  5. Latorre-Muro, P. et al. (2021) J. Biol. Chem. 296:100205. 
  6. Vieira, P. et al. (2017) Mol. Genet. Metab. 120:337.
  7. Becker, J. et. al. (2021) Neuropediatrics. 52:398.
  8. Ye, Q. et al. (2023) Nat. Commun. 14:1402. 
  9. Valera, A. et al. (1994) Proc. Natl. Acad. Sci. USA . 91:9151.
  10. Beale, E.G. et al. (2004) Trends Endocrinol. Metab. 15:129.
  11. Beale, E.G. et al. (2007) Cell Biochem. Biophys. 48:89.
  12. Xu D. et al. (2020) Nature.580:530.
  13. Fei, S. et al. (2021) Front. Oncol. 11:561247.
  14. Fei, S. et al. (2021) Eur. J. Cancer. 142:123.
  15. Liu, N. et al. (2024) Cell Death Discov. 10:478. 
  16. Xiao-Ren, Z. et al. (2021) Cell Death Dis. 12:918.
  17. Xianfei, Z. et al. (2022) Crit. Rev. Eukaryot. Gene Expr.32:35.
  18. Shi, L. et al. (2020) Onco. Targets Ther.13:2613.

Long Name

Phosphoenolpyruvate Carboxykinase 1

Alternate Names

PEPCK-C, PEPCK1

Entrez Gene IDs

5105 (Human); 18534 (Mouse); 362282 (Rat)

Gene Symbol

PCK1

UniProt

P35558.3

Additional PCK1 Products

Product Documents for Recombinant Human PCK1/PEPCK1 His-tag Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human PCK1/PEPCK1 His-tag Protein, CF

For research use only

Privacy Policy
Cookie Policy
Site Map
© Copyright 2026 Bio-Techne. All Rights Reserved. All trademarks and registered trademarks are the property of Bio-Techne and its brands unless otherwise specified.